Free tool
FAERS Monitor: Lysodren
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016885 or its brand name (Lysodren, Mitotane). Reports on generic versions are filed under their own applications.
Reports
1,830
Serious
1,299
71% of reports
Hospitalization
499
Death reported
237
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea319
- off label use307
- fatigue291
- diarrhoea173
- vomiting157
- product dose omission issue142
- adrenal insufficiency134
- drug ineffective132
- dizziness120
- decreased appetite117
- asthenia105
- death88
- malignant neoplasm progression82
- disease progression78
- drug interaction74
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 7 |
| 2006 | 8 |
| 2007 | 27 |
| 2008 | 26 |
| 2009 | 30 |
| 2010 | 18 |
| 2011 | 39 |
| 2012 | 58 |
| 2013 | 38 |
| 2014 | 21 |
| 2015 | 43 |
| 2016 | 41 |
| 2017 | 59 |
| 2018 | 122 |
| 2019 | 55 |
| 2020 | 82 |
| 2021 | 114 |
| 2022 | 171 |
| 2023 | 180 |
| 2024 | 228 |
| 2025 | 193 |
| 2026 | 257 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| adrenal insufficiencySignal | 134 | 128.3 | 108.9 | 16,625 |
| malignant neoplasm progressionSignal | 82 | 9.2 | 7.5 | 594 |
| disease progressionSignal | 78 | 7.6 | 6.1 | 441 |
| decreased appetiteSignal | 117 | 5.8 | 4.9 | 464 |
| product dose omission issueSignal | 142 | 5.6 | 4.7 | 533 |
| drug interactionSignal | 74 | 5.4 | 4.3 | 260 |
| nauseaSignal | 319 | 4.6 | 4.2 | 940 |
| fatigueSignal | 291 | 4.3 | 3.9 | 761 |
| off label useSignal | 307 | 4.0 | 3.6 | 727 |
| vomitingSignal | 157 | 3.8 | 3.3 | 334 |
| astheniaSignal | 105 | 3.2 | 2.7 | 160 |
| diarrhoeaSignal | 173 | 3.1 | 2.7 | 249 |
| dizzinessSignal | 120 | 2.8 | 2.3 | 137 |
| death | 88 | 1.2 | 1.0 | 2 |
| drug ineffective | 132 | 1.2 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.